Karyopharm Therapeutics logo

Karyopharm Therapeutics share price today

(KPTI)

Karyopharm Therapeutics share price is $0.64 & ₹54.38 as on 21 Dec 2024, 2.30 'hrs' IST

$0.64

-0.01

(-2.25%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Karyopharm Therapeutics share price in Dollar and Rupees. Guide to invest in Karyopharm Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Karyopharm Therapeutics. Get details on the Indian mutual funds that are investing in Karyopharm Therapeutics. Get Analyst recommendations and forecasts along with all the Karyopharm Therapeutics's financials.

Karyopharm Therapeutics share price movements

  • Today's Low: $0.63
    Today's High: $0.66

    Day's Volatility :4.39%

  • 52 Weeks Low: $0.63
    52 Weeks High: $1.95

    52 Weeks Volatility :67.94%

Karyopharm Therapeutics Returns

PeriodKaryopharm Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-9.03%
-11.1%
0.0%
6 Months
-42.27%
-6.0%
0.0%
1 Year
-22.94%
2.7%
0.0%
3 Years
-91.09%
0.6%
-19.7%

Karyopharm Therapeutics Key Statistics

in dollars & INR

Previous Close
$0.6496
Open
$0.64
Today's High
$0.6589
Today's Low
$0.63
Market Capitalization
$80.1M
Today's Volume
$1.3M
52 Week High
$1.95
52 Week Low
$0.6251
Revenue TTM
$148.4M
EBITDA
$-125.6M
Earnings Per Share (EPS)
$-1.05
Profit Margin
-58.93%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-891.05%

How to invest in Karyopharm Therapeutics from India?

It is very easy for Indian residents to invest directly in Karyopharm Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Karyopharm Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Karyopharm Therapeutics or KPTI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Karyopharm Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Karyopharm Therapeutics shares which would translate to 1.328 fractional shares of Karyopharm Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Karyopharm Therapeutics, in just a few clicks!

Returns in Karyopharm Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Karyopharm Therapeutics investment value today

Current value as on today

₹1,24,147

Returns

₹24,147

(+24.15%)

Returns from Karyopharm Therapeutics Stock

₹21,951 (false-21.95%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Karyopharm Therapeutics

0%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Karyopharm Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 0% more investors are searching Karyopharm Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Karyopharm Therapeutics

  • Vanguard Group Inc

    6.11%

  • Eversept Partners, LLC

    4.43%

  • Palo Alto Investors, LLC

    4.07%

  • Adage Capital Partners Gp LLC

    3.45%

  • BlackRock Inc

    3.33%

  • Citadel Advisors Llc

    2.48%

Analyst Recommendation on Karyopharm Therapeutics

Buy

    84%Buy

    15%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Karyopharm Therapeutics(by analysts ranked 0 to 5 stars)

Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
3
Sell
0
0
0

Analyst Forecast on Karyopharm Therapeutics

What analysts predicted

Upside of 603.13%

Current:

$0.64

Target:

$4.50

Insights on Karyopharm Therapeutics

  • Price Movement

    In the last 3 years, KPTI stock has moved down by -90.5%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 42.78M → 38.78M (in $), with an average decrease of 9.4% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 23.79M → -32.07M (in $), with an average decrease of 234.8% per quarter
  • KPTI vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 52.0%
  • KPTI vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 113.5%
  • Price to Sales

    ForKPTI every $1 of sales, investors are willing to pay $0.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Karyopharm Therapeutics Technicals Summary

Sell

Neutral

Buy

Karyopharm Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Karyopharm Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Karyopharm Therapeutics Inc
-18.34%
-42.27%
-22.94%
-91.09%
-96.69%
Regeneron Pharmaceuticals, Inc.
-5.73%
-34.03%
-17.11%
13.66%
87.56%
Biontech Se
4.48%
30.56%
7.36%
-56.46%
225.6%
Alnylam Pharmaceuticals, Inc.
-0.55%
10.11%
28.49%
30.99%
109.19%
Vertex Pharmaceuticals Incorporated
-11.79%
-16.36%
-1.97%
78.33%
80.59%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Karyopharm Therapeutics Inc
NA
NA
-0.15
-0.75
-8.91
-0.34
NA
-1.27
Regeneron Pharmaceuticals, Inc.
17.51
17.51
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.17
0.55
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Karyopharm Therapeutics Inc
Buy
$80.1M
-96.69%
NA
-58.93%
Regeneron Pharmaceuticals, Inc.
Buy
$77.8B
87.56%
17.51
33.61%
Biontech Se
Buy
$26.7B
225.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.8B
109.19%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$102.1B
80.59%
32.84
-4.51%

About Karyopharm Therapeutics

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Organization
Karyopharm Therapeutics
Employees
325
CEO
Mr. Richard A. Paulson M.B.A.
Industry
Health Technology

Management People of Karyopharm Therapeutics

NameTitle
Mr. Richard A. Paulson M.B.A.
President, CEO & Director
Ms. Sohanya Cheng M.B.A.
Executive VP, Chief Commercial Officer & Head of Business Development
Mr. Stuart Poulton
Executive VP & Chief Development Officer
Dr. Reshma Rangwala M.D., Ph.D.
Executive VP, Chief Medical Officer & Head of Research
Dr. Mansoor Raza Mirza M.D.
Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Dr. Sharon Shacham M.B.A., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Ms. Kristin Abate
VP, Chief Accounting Officer, Interim Principal Financial Officer & Assistant Treasurer
Mr. Brendan Twohig Strong
SVP of Investor Relations & Corporate Communications
Mr. Michael J. Mano J.D.
Senior VP, General Counsel & Secretary
Mr. James Accumanno J.D.
Chief Compliance Officer

Important FAQs about investing in Karyopharm Therapeutics from India :

What is Karyopharm Therapeutics share price today?

Karyopharm Therapeutics share price today stands at $0.64, Open: $0.64 ; Previous Close: $0.65 ; High: $0.66 ; Low: $0.63 ; 52 Week High: $1.95 ; 52 Week Low: $0.63. The stock opens at $0.64, after a previous close of $0.65. The stock reached a daily high of $0.66 and a low of $0.63, with a 52-week high of $1.95 and a 52-week low of $0.63.

Can Indians buy Karyopharm Therapeutics shares?

Yes, Indians can invest in the Karyopharm Therapeutics (KPTI) from India.

With INDmoney, you can buy Karyopharm Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Karyopharm Therapeutics at zero transaction cost.

How can I buy Karyopharm Therapeutics shares from India?

It is very easy to buy Karyopharm Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Karyopharm Therapeutics be purchased?

Yes, you can buy fractional shares of Karyopharm Therapeutics with INDmoney app.

What are the documents required to start investing in Karyopharm Therapeutics stocks?

To start investing in Karyopharm Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Karyopharm Therapeutics

Today’s highest price of Karyopharm Therapeutics (KPTI) is $0.66.

Today’s lowest price of Karyopharm Therapeutics (KPTI) is $0.63.

What is today's market capitalisation of Karyopharm Therapeutics

Today's market capitalisation of Karyopharm Therapeutics KPTI is 80.1M

What is the 52 Week High and Low Range of Karyopharm Therapeutics

  • 52 Week High

    $1.95

  • 52 Week Low

    $0.63

What are the historical returns of Karyopharm Therapeutics?

  • 1 Month Returns

    -18.34%

  • 3 Months Returns

    -42.27%

  • 1 Year Returns

    -22.94%

  • 5 Years Returns

    -96.69%

Who is the Chief Executive Officer (CEO) of Karyopharm Therapeutics

Mr. Richard A. Paulson M.B.A. is the current Chief Executive Officer (CEO) of Karyopharm Therapeutics.